{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-negative+Metastatic+Breast+Cancer", "query": { "condition": "HER2-negative Metastatic Breast Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 396, "total_pages": 40, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-negative+Metastatic+Breast+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T06:04:22.037Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00958971", "title": "Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "TKI258", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 43, "start_date": "2009-07", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-07-22T06:04:22.037Z", "location_count": 18, "location_summary": "Bakersfield, California • Beverly Hills, California • Los Angeles, California + 13 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redondo Beach", "state": "California" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00958971" }, { "nct_id": "NCT00938652", "title": "A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "gemcitabine/carboplatin", "type": "DRUG" }, { "name": "Iniparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 519, "start_date": "2009-07", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2013-09-19", "last_synced_at": "2026-07-22T06:04:22.037Z", "location_count": 102, "location_summary": "Birmingham, Alabama • Sedona, Arizona • Jonesboro, Arkansas + 98 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00938652" }, { "nct_id": "NCT05216432", "title": "First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "PIK3CA Mutation", "Solid Tumor, Adult", "HER2-negative Breast Cancer", "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer", "Unresectable Solid Tumor" ], "interventions": [ { "name": "RLY-2608", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Palbociclib 125mg", "type": "DRUG" }, { "name": "Ribociclib 400mg", "type": "DRUG" }, { "name": "Ribociclib 600mg", "type": "DRUG" }, { "name": "PF-07220060 100mg", "type": "DRUG" }, { "name": "PF-07220060 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Relay Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 930, "start_date": "2021-12-08", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-07-22T06:04:22.037Z", "location_count": 24, "location_summary": "Tucson, Arizona • San Diego, California • Denver, Colorado + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05216432" }, { "nct_id": "NCT04182516", "title": "Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumors" ], "interventions": [ { "name": "NMS-03305293", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nerviano Medical Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2019-11-25", "completion_date": "2024-05-16", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-07-22T06:04:22.037Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04182516" }, { "nct_id": "NCT07227233", "title": "Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant.", "type": "DRUG" }, { "name": "Treatment of physician's choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2026-03-31", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-07-22T06:04:22.037Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227233" }, { "nct_id": "NCT00540358", "title": "A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "gemcitabine/carboplatin", "type": "DRUG" }, { "name": "iniparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 123, "start_date": "2007-10", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2012-12-28", "last_synced_at": "2026-07-22T06:04:22.037Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Denver, Colorado • Torrington, Connecticut + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Denver", "state": "Colorado" }, { "city": "Torrington", "state": "Connecticut" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00540358" }, { "nct_id": "NCT00003440", "title": "Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-negative Breast Cancer", "HER2-positive Breast Cancer", "Recurrent Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 580, "start_date": "1998-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-07-22T06:04:22.037Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003440" }, { "nct_id": "NCT07137871", "title": "Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer Metastatic" ], "interventions": [ { "name": "Avasopasem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2025-10-02", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2025-10-31", "last_synced_at": "2026-07-22T06:04:22.037Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07137871" }, { "nct_id": "NCT07067138", "title": "A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Breast Carcinoma", "Cancer of the Breast", "Malignant Neoplasm of Breast" ], "interventions": [ { "name": "Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT)", "type": "DEVICE" }, { "name": "TruSight(R) Oncology 500", "type": "DEVICE" }, { "name": "TruSeq Matched Tumor Normal Whole Exome Sequencing Assay", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 175, "start_date": "2026-02-23", "completion_date": "2029-08-04", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-07-22T06:04:22.037Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07067138" }, { "nct_id": "NCT01576666", "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dose Escalation", "Safety", "Preliminary Efficacy", "Advanced Solid Tumors", "Metastatic Breast Cancer", "Advanced Pancreatic Adenocarcinoma", "Metastatic Colorectal Cancer", "Recurrent Glioblastoma Multiforme", "Gastric Cancer", "Gastroesophageal Junction Cancer", "Triple Negative Metastatic Breast Cancer", "Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer" ], "interventions": [ { "name": "LDE225", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2012-07", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-07-22T06:04:22.037Z", "location_count": 13, "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01576666" } ] }